Ignite Creation Date:
2024-05-06 @ 2:39 AM
Last Modification Date:
2024-10-26 @ 11:21 AM
Study NCT ID:
NCT02094573
Status:
COMPLETED
Last Update Posted:
2021-03-15
First Post:
2014-03-18
Brief Title:
A Study to Evaluate the Efficacy of Brigatinib AP26113 in Participants With Anaplastic Lymphoma Kinase ALK-Positive Non-small Cell Lung Cancer NSCLC Previously Treated With Crizotinib
Sponsor:
Organization:
Takeda
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
222
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: